Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer

BACKGROUND: First‐line chemoimmunotherapy (CIT) has improved overall survival (OS) and progression‐free survival (PFS) outcomes among patients with non‐small cell lung cancer (NSCLC). The immunological and nutritional statuses of patients fluctuate during treatment using immune checkpoint inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Yuri, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Tani, Nozomi, Sato, Izumi, Hirose, Kazuki, Kato, Daishiro, Takeda, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779203/
https://www.ncbi.nlm.nih.gov/pubmed/33124197
http://dx.doi.org/10.1111/1759-7714.13720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779203/
https://www.ncbi.nlm.nih.gov/pubmed/33124197
http://dx.doi.org/10.1111/1759-7714.13720

Ejemplares similares